Pharma major Lupin announced that it has received approval for its Budesonide Inhalation Suspension, 0.5 mg/2 mL Single-Dose Ampules from the United States Food and Drug Administration (FDA) to market a generic version of AstraZeneca Pharmaceuticals LP's (AstraZeneca) Pulmicort Respules Inhalation Suspension, 0.5 mg/2 mL.
Lupin's Budesonide Inhalation Suspension, 0.5 mg/2 mL Single-Dose Ampules is the generic version of AstraZeneca's Pulmicort Respules Inhalation Suspension, 0.5 mg/2 mL. It is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age.
Budesonide Inhalation Suspension, 0.5 mg/2 mL Single-Dose Ampules had annual sales of approximately USD 474.5 million in the US (IQVIA MAT September 2018).
Shares of the company declined Rs 8.5, or 0.99%, to trade at Rs 852.00. The total volume of shares traded was 32,390 at the BSE (1.29 p.m., Tuesday).